State regulators are increasing oversight of AI mental health chatbots as new research reveals potential harms, including a Stanford study finding that chatbots worsen loneliness for isolated users, while clinicians call for companies to disclose safety data following multiple crisis incidents.
Researchers at Washington University have discovered that severe childhood stress creates lasting changes to DNA packaging inside brain cells, forming a molecular memory of trauma that makes individuals more vulnerable to anxiety, depression, and mood disorders when facing stress as adults.
Researchers at Washington University have discovered that severe childhood stress creates lasting changes to DNA packaging inside brain cells, forming a molecular memory of trauma that makes individuals more vulnerable to anxiety, depression, and mood disorders when facing stress as adults.
A recent clinical trial found that a single dose of ketamine increases morning cortisol levels in suicidal patients for up to 24 hours, potentially explaining the drug's rapid antidepressant and anti-suicidal effects. The finding adds to understanding of ketamine's therapeutic mechanisms beyond its original use as an anesthetic.
A randomized controlled trial conducted through the NHS in England found that a single dose of psilocybin, the active compound in magic mushrooms, produced significant improvements in depression symptoms among 60 adults with treatment-resistant major depressive disorder compared to placebo, with good tolerability.
Researchers demonstrate fingertip sensors can identify physical patterns linked to stress, anxiety and depression, while major wearable companies including Whoop, Oura, and Apple expand into healthcare applications. Amae Health partners with Google Health to integrate Fitbit and voice biomarkers for precision psychiatry.
Scientists at The University of Texas MD Anderson Cancer Center have discovered common neuroimmune signatures that may explain how rapid-acting antidepressants like ketamine and psychedelics work to reduce symptoms in treatment-resistant depression.
Compass Pathways reported results from a pivotal study showing its psilocybin-based therapy demonstrated long-lasting benefits for treatment-resistant depression, though investor reaction was mixed as shares fell nearly 10% on the data.
Definium Therapeutics reported that a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending shares higher. The data brings the drug closer to potential FDA approval.
Health officials under Robert F. Kennedy Jr. explored banning certain SSRI antidepressants as part of plans to reduce their use in the United States, sparking significant debate over medication safety and federal regulatory authority.
Medical professionals and patients on social media are increasingly reporting a phenomenon called 'Ozempic personality,' characterized by emotional flattening and reduced ability to experience joy while taking GLP-1 medications for weight loss.
